Down-regulation of β-adrenergic receptors on mononuclear leukocytes induced by dobutamine treatment in patients with congestive heart failure

J. K. Teng, C. M. Kwan, L. J. Lin, L. M. Tsai, J. T. Cheng, W. C. Chang, J. H. Chen

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

(±)-Dobutamine is a positive inotropic drug usually used to improve ventricular function in patients with congestive heart failure (CHF). However, it has been found that haemodynamic responses to dobutamine become blunted during continuous treatment. In this study we determined the time-dependent changes of β-adrenergic receptors in CHF patients treated with dobutamine. Seven CHF patients received a continuous intravenous infusion of dobutamine (5 μg . kg-1 . min-1) for 96 h. Blood samples were obtained before and every 24 h after starting the therapy. The density of β-adrenergic receptors on mononuclear leukocytes and the plasma concentrations of norepinephrine and epinephrine were determined. During dobutamine treatment the receptor density (fmol . mg-1, mean ± SEM) gradually decreased from 42.8 ± 4.4 (baseline) to 31.4 ± 3.3 (P

Original languageEnglish
Pages (from-to)1349-1353
Number of pages5
JournalEuropean Heart Journal
Volume14
Issue number10
Publication statusPublished - 1993
Externally publishedYes

Keywords

  • β-adrenergic receptor
  • Congestive heart failure
  • Dobutamine
  • Down-regulation
  • Drug tolerance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Physiology

Fingerprint Dive into the research topics of 'Down-regulation of β-adrenergic receptors on mononuclear leukocytes induced by dobutamine treatment in patients with congestive heart failure'. Together they form a unique fingerprint.

Cite this